Last reviewed · How we verify
TA-7284 High
TA-7284 High is a Angiotensin II receptor antagonist Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Hypertension.
TA-7284 High is a drug that targets the renin-angiotensin system.
TA-7284 is a small molecule being studied for its effects on Type 2 Diabetes Mellitus. It is being tested in a clinical trial with two different dose levels, TA-7284 Low and TA-7284 High, in addition to a placebo.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TA-7284 High |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the angiotensin II receptor type 1, which plays a key role in blood pressure regulation. This leads to vasodilation and a decrease in blood pressure. Additionally, it may have protective effects on the kidneys.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment (PHASE1)
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus (PHASE3)
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes (PHASE2)
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TA-7284 High CI brief — competitive landscape report
- TA-7284 High updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI
Frequently asked questions about TA-7284 High
What is TA-7284 High?
How does TA-7284 High work?
What is TA-7284 High used for?
Who makes TA-7284 High?
What drug class is TA-7284 High in?
What development phase is TA-7284 High in?
What are the side effects of TA-7284 High?
What does TA-7284 High target?
Related
- Drug class: All Angiotensin II receptor antagonist drugs
- Target: All drugs targeting AT1 receptor
- Manufacturer: Tanabe Pharma Corporation — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing